Speakers
J Ryan Shaw, PharmD, BCPS, BCOP, CPP is a clinical pharmacist practitioner of Bone Marrow Transplant and Cellular Therapy at the University of North Carolina Medical Center and an adjunct assistant professor of Clinical Education at UNC Eshelman School of Pharmacy.
Sara Scott, PharmD, BCOP is an oncology plinical Pharmacy specialist at Emory Healthcare, Winship Cancer Institute.
Kelley L. Julian, PharmD, BCOP, is a hematology/bone marrow transplant pharmacy supervisor and a PGY2 Oncology Pharmacy Residency Program director at Huntsman Cancer Institute, University of Utah.
In this episode of Pharmacy Focus: Oncology Edition, oncology pharmacy experts J Ryan Shaw, PharmD, BCPS, BCOP, CPP; Sara Scott, PharmD, BCOP; and Kelley L. Julian, PharmD, BCOP, discuss the evolving landscape of BCMA-targeted therapies, including bispecific antibodies and CAR T-cell therapies such as ciltacabtagene autoleucel (cilta-cel, Carvykti; Janssen) and idecabtagene vicleucel (ide-cel, Abecma; Bristol Myers Squibb). They explore the mechanisms, administration protocols, and safety considerations of these therapies, highlighting their impact on patient outcomes in multiple myeloma.
The speakers provide practical guidance on patient selection, monitoring for adverse events like cytokine release syndrome and neurotoxicity, and managing care across multidisciplinary teams. They emphasize the growing role of oncology pharmacists in navigating logistical challenges and ensuring the safe, effective delivery of advanced cellular therapies. The discussion underscores both the promise of BCMA-targeted treatments and the critical contributions of pharmacists in optimizing therapy for patients.
